A voluntary market withdrawal of orally administered, over-the-counter cough and cold medications (CCMs) labeled for infants was announced in October 2007 because of concerns regarding limited evidence of efficacy and potential harmful effects of these products among young children.
The use of cough and cold medications (CCMs) for children recently garnered increased attention because of concerns regarding the potential harmful effects of these medications when used inappropriately and limited evidence for their efficacy, particularly for infants and young children. [1] [2] [3] [4] [5] [6] [7] [8] [9] On October 11, 2007, on behalf of the leading makers of over-the-counter (OTC) CCMs, the Consumer Healthcare Products Association announced a voluntary market withdrawal of orally administered CCMs labeled or intended for infants. 10 This was followed by a US Food and Drug Administration (FDA) recommendation on January 17, 2008 , to avoid use of these products to treat infants and children Ͻ2 years of age, "because serious and potentially lifethreatening side effects can occur." 11 Here, we use nationally representative public health surveillance data to assess potential changes in the number of emergency department (ED) visits because of CCM-related adverse events (AEs) after announcement of the withdrawal of OTC products for infants.
METHODS
National estimates of ED visits for AEs were based on surveillance cases from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NIESS-CADES) project, which involves a nationally stratified, probability sample of 63 hospitals in the United States and its territories with a minimum of 6 beds and a 24-hour ED. 12 All hospitals treat pediatric patients, and 5 are pediatric specialty hospitals. The NEISS-CADES project is a collaboration of the Centers for Disease Control and Prevention (CDC), the FDA, and the US Consumer Product Safety Commission and was described previously. 12, 13 In brief, trained coders at each hospital review clinical records of ED visits to identify physician-diagnosed AEs, report up to 2 medications implicated in the AE, and record narrative descriptions of the incidents. Narrative descriptions are coded by using the Medical Dictionary for Regulatory Activities, an international terminology system used to analyze AE reports.
Surveillance cases included any incident ED visit by a patient Ͻ12 years of age because of a condition that was attributed to a medication (any prescription or OTC drug product, including vitamins, herbal remedies/dietary supplements, and vaccines) in the ED medical record and that occurred in the 14-month period before announcement of the market withdrawal of orally administered, OTC, infant CCMs (July 22, 2006, to October 11, 2007 ; referred to here as the prewithdrawal period) or in the 14-month period after announcement of the withdrawal (October 12, 2007, to December 31, 2008 ; referred to here as the postwithdrawal period). These periods were chosen because, at the time of this evaluation, weighted data enabling national estimates were available only through the end of 2008. CCMs were defined as orally administered prescription or OTC products containing decongestants, antitussive agents/expectorants, or decongestant, antihistamine, antitussive agent, and/or expectorant combinations.
ED visits were classified as attributable to "unsupervised ingestions" when cases involved children accessing medications without adult permission or oversight and as "supervised administrations" when medications were given to children by caregivers. Medication errors were defined as any errors made during the prescribing, dispensing, or administration of the medication, as documented in the ED medical record. ED visits were excluded if they were attributed to drug abuse or harmful intent or if the AE occurred during the ED visit.
Each selected NEISS-CADES case was accompanied by a sample weight based on the inverse probability of selection, with adjustment for nonresponse rate and poststratification to adjust for the number of annual hospital ED visits. National estimates of ED visits and corresponding 95% confidence intervals (CIs) were calculated by using the Surveymeans procedure in SAS 9.2 (SAS Institute, Cary, NC) to account for weighting and complex sample design. National estimates based on Ͻ20 cases were considered statistically unstable and are not shown; therefore, some analyses are descriptive and are based on the number of surveillance cases rather than on national estimates. Estimates with a coefficient of variation of Ͼ30% are indicated in the tables.
To compare patterns of ED visits for AEs between the prewithdrawal and postwithdrawal periods, we used the Surveymeans procedure to estimate selected proportions (eg, the proportions of CCM-related ED visits involving children Ͻ2 years of age) for the 2 periods. The estimated proportions (and variances) were then used to estimate before/after differences and accompanying 95% CIs. 14 Because the prewithdrawal and postwithdrawal periods did not overlap, estimated proportions for the respective periods were treated as statistically independent.
RESULTS

National Estimates
In the 14-month period after announcement of the withdrawal of orally administered, OTC CCMs for infants, the number and proportion of estimated ED visits for CCM-related AEs involving children Ͻ2 years of age were less than one-half of those in the prewithdrawal period (1248 visits [13 When results were examined according to age group, the types of CCM ingestions leading to ED visits for AEs also remained relatively unchanged in the prewithdrawal and postwithdrawal periods ( 
DISCUSSION
The use of CCMs for children remains an important concern in the medical and public health communities. In the 14-month period after announcement of the withdrawal, the numbers and proportions of estimated ED visits for CCM-related AEs involving children Ͻ2 years of age were reduced by more than one-half, compared with the 14-month period before the announcement. Because of the relatively large numbers of unsupervised ingestions of CCMs among children 2 to 5 years of age, however, the overall numbers of ED visits for CCM-related AEs and the contribution of CCMs to the total medication-related ED visit burden remained unchanged for children Ͻ12 years of age. A recent study documented a significant reduction in the mean annual rate of calls reported to US poison control centers that involved therapeutic errors with OTC CCMs among children Ͻ2 years of age in the 15 months after withdrawal, relative to a 27-month prewithdrawal period. Because calls to poison control centers are voluntary, however, an impact of reporting bias on the findings could not be excluded and the incidence of national exposures could not be calculated. 15 To our knowledge, ours is the first report that, on the basis of active surveillance, assessed the changes in the national burden and scope among children of CCMrelated AEs and AEs related to medications potentially substituted for infant CCMs since the announcement of the withdrawal of orally administered OTC products marketed for infants. Although these safety data cannot be used in isolation to dictate clinical or regulatory actions, our findings have important implications for continued efforts to reduce the burden of harm resulting from these medications.
First, the finding of a substantial reduction in estimated ED visits for CCMrelated AEs among children Ͻ2 years of age after announcement of the market withdrawal is especially important because, after the withdrawal, some caregivers might have maintained belief in the overall safety and efficacy of these products or might have been unaware of or misinterpreted warnings and either administered infant products still present in the home or substituted products labeled for older children and adults. [16] [17] [18] [19] [20] A related concern regarding the withdrawal of infant CCMs was that caregivers might have sought other treatments to relieve cough and cold symptoms, which might have resulted in inappropriate use of some medications (eg, antibiotics) or increased the burden of harm from others (eg, analgesics). In a survey of 1265 parents conducted between March and May 2008 at 20 pediatric offices, 27% of parents with children Ͻ2 years of age stated that they were more likely to request an antibiotic from the doctor after market withdrawal of infant CCMs. 19 Although we could not account directly for changes in patterns of medication use, we did not identify any significant changes in the estimated numbers or proportions of ED visits for AEs resulting from supervised administrations of antibiotics or other medications that might have been substituted for cough and cold relief for children Ͻ2 years of age. Overall, the finding of a reduction in ED visits for children Ͻ2 years of age is encouraging, but continued education of clinicians and caregivers and further monitoring likely will be needed to ensure that the burden of CCM-related harm continues to decrease for young children, espe- cially given recent recommendations to avoid CCMs for children Ͻ4 years of age. 21, 22 Second, although medication errors contributed to few ED visits overall, the errors that did occur were almost exclusively the result of caregivers overdosing liquid formulations of CCMs. This finding is important, because administrationrelated medication errors constitute a large proportion of drug-related AEs that are considered to be readily preventable in pediatric outpatient settings. 23, 24 For liquid medications intended for children, it has been suggested that administrationrelated medication errors stem from caregiver misunderstanding of labeling instructions, failure to distinguish between certain volumetric measures (eg, "tsp" versus "tbsp"), or confusion resulting from inconsistency of dosing device markings with the labeled dosage directions 25 and that these types of errors can be prevented through the use of moreaccurate dosing instruments (eg, droppers, dosing spoons, and syringes versus dosing cups). [25] [26] [27] [28] One recent development that may prevent these types of medication errors in the future is a shift toward improved industry standards for displaying volumetric measures on liquid medication labels and dosing devices. 29, 30 In collaboration with the "CDC", the FDA, and other stakeholders, Consumer Healthcare Products Association manufacturers recently adopted voluntary guidance to simplify and to standardize volumetric measures used in the labeling of children's OTC, orally administered, liquid medications and their respective dosing devices. 29 The FDA recently released similar draft guidance for industry, aimed at improving the clarity and consistency of dosage delivery devices packaged with newly approved OTC, orally administered, liquid medications. 30 Future studies will be required to assess the impact of these new guidelines on harm resulting from CCMs and other liquid medications.
Third, unsupervised ingestions remained the primary cause of harm resulting from CCMs for children Ͻ12 years of age, and preschoolaged children (2-5 years) continued to account for most CCM-related AEs. These findings point to the need for continued interventions targeted at reducing the potential for harm when children find and ingest medications. To that end, we previously suggested engineering innovations, including packaging improvements designed to minimize unsupervised ingestions of liquid medications. 31 Examples of such innovations include incorporation of adaptors on liquid medication bottles, so that the medication could be accessed only with a needleless syringe, or the use of bottle-neck flow restrictors that would limit the amount of liquid that could be ingested if an unsupervised child gained access to the medication.
Our findings are subject to a few important limitations. First, surveillance through the NEISS-CADES project likely underestimates the total burden of AEs resulting from CCMs because it does not identify AEs resulting in calls to poison control centers, visits to outpatient physician offices, or deaths; however, the ED is probably the best single setting to identify serious AEs, because it is the location where children with serious symptoms most likely would be brought for treatment. Second, the NEISS-CADES project relies on assessment and documentation by ED physicians; therefore, it is more likely to identify well-recognized AEs (eg, unsupervised ingestions) and is less likely to identify AEs that are rare, previously unreported, or difficult to diagnose in the ED setting. 12, 13 Third, information on the specific CCM formulation (ie, infant versus pediatric versus adult) implicated in the AE was not available in some cases, which limited our ability to draw conclusions about specific products. Fourth, we cannot comment on whether changes in the number of ED visits differed according to race/ ethnicity, socioeconomic status, or caregiver health literacy, because information about these variables is limited or unavailable through the NEISS-CADES project. Fifth, although our findings suggest that removal of infant products from the market likely contributed to the reduction of CCMrelated morbidity among children Ͻ2 years of age, other factors, including widespread attention in the media to the issue of the safety and efficacy of CCMs, changes in provider attitudes and recommendations, and warnings issued by the FDA, also might have affected use of these medications and ED visits for CCM-related AEs in this age group. Lastly, there may be a seasonality component to CCM use, with less use of these products in the summer months and subsequently fewer ED visits for CCMrelated AEs. Therefore, the selection of 14-month periods before and after the announcement of market withdrawal in October 2007 might have favored higher estimates of the number of ED visits for the postwithdrawal period, relative to the prewithdrawal period of the same duration, however, this further strengthens the finding that ED visits among children Ͻ2 years of age were reduced.
Future work will be needed to assess the impact of more-recent labeling changes to avoid the use of CCMs for children Ͻ4 years of age 21, 22 
